A. Karim Kader, MD, PhD, presented “Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro Argument” during the 28th Annual Perspectives in Urology: Point Counterpoint on November 16, 2019 in Scottsdale, Arizona.

How to cite: Kader, A. Karim. Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro Argument” November 16, 2019. Accessed Feb 2020. https://grandroundsinurology.com/prostate-cancer-screening-and-early-detection-should-we-follow-the-nccn-guidelines-pro-argument/

Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro Argument -Summary:

A. Karim Kader, MD, PhD, argues that although PSA-based prostate cancer screening is flawed, urologists should adhere to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Screening and Early Detection Guidelines. He outlines how, in order to avoid overdiagnosis and other issues, urologists can be more judicious as to which patients are offered screening, biopsy, and treatment, while not abandoning the use of PSA as a marker for prostate cancer altogether. 

The “con” rebuttal to this presentation is “Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con Argument” by Robert E. Donohue, MD.

About Perspectives in Urology: Point Counterpoint

Perspectives in Urology: Point Counterpoint (PCP) is an annual, multi-day, CME-accredited conference devoted to discussing and debating the latest topics in men’s health and general urology, as well as management of bladder, renal, and both localized and advanced prostate cancer. More than didactic lectures, the conference’s format includes debates, point-counterpoint discussion panels, and unique case-based presentations. Dr. Kader presented this lecture during the 28th PCP in 2019. Please visit this page in order to register for future PCP meetings.